Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res (2016) 22(5):1173 –84. doi: 10.1158/1078-0432.CCR-15-1352 16. Duffy AG, Ulahannan SV, Makrova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients withadvanced hepatocellular carcinoma. J Hepatol (2017) 66(3):545 –51. doi: 10.1016/ j.jhep.2016.10.029Shou et al. 10.3389/ ﬁmmu.2022.1000681 Frontiers in Immunology frontiersin.org 15 17. Löf ﬂer MW, Nussbaum B, Jäger G, Jurmeister PS, Budczies J, Pereira PL, et al. A non-interventional clinical trial assessing immune responses afterradiofrequency ablation of liver m etastases from colorectal cancer. Front Immunol (2019) 10:2526.